Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive ...
Lilly's GLP-1 drugs Mounjaro and Zepbound drive revenue growth International sales of Mounjaro help extend Lilly's marker lead Investors eye Foundayo's US launch as test for future obesity-drug market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results